太阳集团城2018网站(澳门)股份有限公司-MBA智库百科

About US

关于我们

1992

1995

2003

2005

2011

2012

2014

2015

2016

2017

2018

2019

2020

2021

2022

1992


  • Hainan Poly Pharm was Founded

1995


  • Poly Launched its First Product Nimodipine Capsules to Market

2003


  • Zhejiang Poly Pharm was Established

2005


  • cGMP Certification Launched to Start a New Journey of Internationalization

2011


  • Production Line of Ganciclovir Sodium for Injection and its API Passed WHO on-site GMP Inspection

2012


  • 1. Hainan Poly Pharm Changed to be a Joint-stock Company;

  • 2. Production Line of Ganciclovir Sodium for Injection and its API Passed EU EMA On-site GMP Inspection;

  • 3. Product Approved to WHO pre-qualification Program

2014


  • Ganciclovir sodium for injection receives EU marketing authorization

2015


  • Production Line of Lyophilized Powder Injection Passed US FDA Inspection

2016


  • EU Marketing Authorization Obtained for Levetiracetam Injection

2017


  • Poly Pharma Successfully Listed in Growth Enterprise Board

2018

1. Facility of Hangzhou Poly Pharm Put into Operation;

2. New Injection Building and Upgraded API Workshop of Hainan Poly Pharm Put into Operation;

3. API Workshop and Lyophilized Injection Line Passed WHO GMP Follow-up Inspection

2019

Anhui Poly Pharm Laid Foundation Stone for its Manufacturing Facility

2020

1. First Shippment of Sodium Nitroprusside Injection to the United States;

2. Bivalirudin for Injection Approved for Marketing in China;

3. Ganciclovir Sodium for Injection Passed Consistency Evaluation.

2021

1. Zhejiang Poly Pharm received EIR for its first pre-approval inspection by FDA

2. Beijing Pharmaceutical Innovation Platform was jointly established by Institute of High Energy Physics (Chinese Academy of Sciences) and Poly Pharm.

3. Poly Pharma Steps into DNA Vaccine;

4. Anqing facility officially start production。

2022

1、Celebrating 30th Anniversary of Poly Pharm Group (1992-2020);

2、Initial Shippment of Esomeprazole Sodium for Injection to the United States;

3、Sodium Nitroprusside Injection passed the evaluation of bio-equivalence consisteny and approved for marketing in China.

XML 地图